An observational study in Traumatic Brain Injury and Venous Thromboembolism, sponsored by University of Minnesota. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University of Minnesota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.
Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 2nd largest by planned enrollment of the 257 observational ones that give a count, is one of 42 that started in 2023, is one of 258 observational ones, reaches primary completion later than 101 of the 249 other live ones, and was the 708th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:
Shirley Ryan AbilityLab · Sites in United States
Ages 18–75
Andrew Mayer · Sites in United States
Ages 18–82 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–55
Columbia University · Sites in United States
Ages 18+
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
909 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 110 · Phase 3 39 · Phase 4 28
First in 1996; this study’s year is marked. 42 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.
Median enrollment 50 across the 650 interventional studies, 120 across the 257 observational. Of the 553 that completed or were terminated, 182 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 909 have an industry lead sponsor. The 10 most frequent:
University of Minnesota is the lead sponsor of 1,219 studies on the registry; 199 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
University of Minnesota has 6 studies filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
83 of the studies in Brain Injuries, Traumatic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT06103201University of Maryland, BaltimoreHyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury | 2026-11-26 |
| NCT07733284Kessler FoundationHome-Based Walking for Thinking Skills in Persons With TBI | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT05702138Craig HospitalHigh Intensity Step Training After Traumatic Brain Injury | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 909 studies in Brain Injuries, Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project will adapt a currently deployed Clinical Decision Support (CDS) system to deliver a VTE prevention guideline for adult patients with traumatic brain injury (TBI). We believe this is an ideal PCOR use case given PCORI's continued effort to combat VTE in trauma and our experience previously implementing this guideline. The Our overall goal is to successfully scale, evaluate, and maintain an interoperable TBI CDS across 7 total institutions.
All patients age 18 and older admitted with a TBI will be eligible for inclusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
healthcare system leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
Other: Observational
healthcare system not leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
Other: Observational-control
There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
There is no intervention, the hospitals will not use the CDS system.
primary effectiveness outcome
VTE event rate
Time frame: 2 years and a half
Evaluate implementation strategy guided by the EPIS Implementation
the number of patients that received treatment according to the best practice guideline and the % adherence to the guideline per site
Time frame: 2 years and a half
Started May 2023 (actual). Primary completion is estimated for Mar 2027, 45 months after the start.
Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 45 months is close to that.
Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → Mar 2027 and completion Sep 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.